Neuroendocrine small cell carcinoma of the prostate: A brief review of pathology, clinical characteristics and treatment guidelines

Stein, Moshe; Kuten, Abraham

doi:10.1007/978-2-287-92246-6_26

Search citation statements

Order By: Relevance

Paper Sections

Select...

Introduction1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2014

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Accounting for <2% of all prostatic primary tumours [ 1 ], small-cell carcinoma of the prostate is a rare, yet highly aggressive variant form of prostate cancer for which optimal treatment strategies have not been established. Prognosis is very poor, with median survival times from diagnosis ranging from 5 to 17.5 months [ 2 ].…”

Section: Introductionmentioning

confidence: 99%

Successful delivery of chemotherapy to treat small-cell prostate cancer in a patient undergoing haemodialysis

McPartlin

Grimaldo

Lyons

et al. 2014

Clinical Kidney Journal

View full text Add to dashboard Cite

We report on the successful treatment of small-cell prostate cancer in a patient undergoing haemodialysis. The therapeutic regimen included 300 mg/m2 of carboplatin and 50 mg/m2 of etoposide coupled with radical radiotherapy. Adjustments to the patient's haemodialysis prescription included the use of high flux, a larger dialyser surface area and an increased dialysis time. The parameters used aided tolerance to the drug, allowing the delivery of safe, effective treatment. At an interval of over 12 months post-treatment the patient shows no clinical evidence of recurrent disease. This case provides evidence to encourage the use of chemotherapy in otherwise potentially undertreated haemodialysed patients.

show abstract

Section: Introductionmentioning

confidence: 99%